Rockville’s NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

Published on :

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in progressive multifocal leukoencephalopathy (PML), a rare but very aggressive, opportunistic brain infection. PML is caused by the reactivation of John Cunningham virus (JCV) in immunocompromised individuals, and there are currently no approved therapies for this illness. This investigator-initiated study is being led by Irene Cortese, M.D., of the National Institute of Neurological Disorders and Stroke (NINDS)/National Institute of Health (NIH).

Commission Appoints Amritha Jaishankar, Ph.D. as Executive Director, Maryland Stem Cell Research Fund (MSCRF)

Published on :

The Maryland Stem Cell Research Commission (Commission) announces the appointment of Amritha Jaishankar, PhD as Executive Director, Maryland Stem Cell Research Fund (MSCRF).

Matan Signs Deal with Ellume for Two Full Buildings at Progress Labs at Center 85

Published on :

Matan Companies announced today the signing of a long-term lease with Ellume, an Australian-based company that develops diagnostic solutions for infectious diseases. The Frederick facility, totaling over 180,000 square feet in two full buildings at Progress Labs at Center 85, will be Ellume’s first in the United States and will produce diagnostic tests for infectious diseases, including at-home rapid tests for COVID-19.

WaPo: Montgomery County to Spend $500,000 on Push for Global Pandemic Center

Published on :

An ambitious push to create a “Global Pandemic Center” in suburban Maryland got a $500,000 boost Tuesday from the Montgomery County Council, which said the project could help drive the county’s post-pandemic economic recovery and foster resilience against the next major health crisis.

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

Published on :

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today [….]

GSK to support manufacture of Novavax’ COVID-19 vaccine

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.

Germantown’s QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio

Published on :

QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency [….]